T Cells Secrete DNA to Enhance Cancer-Fighting Immunity
Published: April 30, 2026
Unlocking the Immune System’s Potential
Researchers at Weill Cornell Medicine have discovered that activated immune cells, specifically T cells, secrete tiny capsules containing DNA that can bolster the body’s defense systems against cancer. This finding, published in Cancer Cell, expands our understanding of immune function and suggests a novel strategy for enhancing immunity and delivering genetic material to cells.
How T Cells Deliver DNA
Like most animal cells, T cells release extracellular vesicles—nanoscale, membrane-bound particles. These vesicles carry a diverse cargo, including proteins and DNA fragments. The study revealed that vesicles from activated T cells deliver DNA directly into both immune cells and nearby tumor cells, amplifying the immune response against cancer. This process effectively boosts the antigen-presenting process, promoting T cell priming and broader immune activation.
Therapeutic Implications
Preclinical experiments indicate that the DNA carried within these vesicles has therapeutic potential. Researchers found that it can enhance T cell attacks on tumors that previously elicited minimal immune response. “These findings reveal a natural mechanism for treating immunologically silent tumors and other diseases that stem from insufficient immune surveillance,” explained Dr. David Lyden, co-senior author of the study and the Stavros S. Niarchos Professor in Pediatric Cardiology at Weill Cornell Medicine.
Extracellular Vesicles: A Growing Area of Research
The Lyden lab has been at the forefront of extracellular vesicle research, previously demonstrating how vesicles secreted by tumor cells can influence the immune system’s anti-tumor response. This latest study builds upon that operate, highlighting the crucial role of vesicles in intercellular communication and immune regulation.
Future Directions
This discovery opens recent avenues for cancer immunotherapy and gene delivery. Further research will focus on harnessing the power of T cell-derived vesicles to develop targeted therapies that can overcome immune evasion and improve treatment outcomes for a wider range of cancers.